Kairos Pharma Ltd

KAPA

0.615USD

+0.025+4.24%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Kairos Pharma Ltd's Score

Industry at a Glance

Industry Ranking

176 / 392

Overall Ranking

330 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Kairos Pharma Ltd Highlights

StrengthsRisks

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -1.99, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 415.57K shares, decreasing 81.29% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 131.83K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

8.333

Target Price

+1312.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Kairos Pharma Ltd is 6.92, ranking 184 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.92

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.84

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Kairos Pharma Ltd is 5.76, ranking 366 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.99, which is -20.29% below the recent high of -1.59 and -736.03% above the recent low of -16.65.

Score

Industry at a Glance

Previous score

5.76

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 176/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Kairos Pharma Ltd is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 12.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Kairos Pharma Ltd is 5.65, ranking 304 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.86 and the support level at 0.48, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.70

Change

-0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Yu (John S)

5.53M

+3.57%

Bhowmick (Neil Ph.D.)

1.30M

+15.20%

Technomedics Management and Systems, Inc

1.17M

--

Murali (Ramachandran Ph.D.)

290.20K

+111.01%

Samuelson (Doug)

257.56K

+145.56%

The Vanguard Group, Inc.

Star Investors

131.83K

+1129.17%

Bae (Hyun W. M.D.)

73.37K

+35.15%

Two Sigma Investments, LP

70.68K

+421.46%

Geode Capital Management, L.L.C.

65.80K

+201.78%

Singhvi (Rahul)

49.20K

+63.36%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Kairos Pharma Ltd. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Kairos Pharma Ltd

KAPA

5.62 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment